- 1 Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation
- 2 among adults in Norway: a national cohort study, July November 2021.
- 3
- 4 Jostein Starrfelt, PhD^{1#}
- 5 Anders Skyrud Danielsen, MPhil^{1,2}
- 6 Eirik Alnes Buanes, PhD ^{3,4}
- 7 Lene Kristine Juvet, PhD^{5,}
- 8 Trude Marie Lyngstad, PhD¹
- 9 Gunnar Øyvind Isaksson Rø, PhD⁶
- 10 Lamprini Veneti, MSc¹
- 11 Sara Viksmoen Watle, MD PhD ⁵
- 12 Hinta Meijerink, PhD⁵
- 13
- 14 Affiliations:
- Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo,
 Norway
- 17 2. Department of Microbiology, Oslo University Hospital
- Norwegian Intensive Care and Pandemic Registry (NIPaR), Helse Bergen Health Trust, Bergen,
 Norway
- Department of Anaesthesiology and Intensive Care Haukeland University Hospital, Bergen,
 Norway
- Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo,
 Norway
- 24 6. Department of Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway
- 25
- 26 [#]Corresponding author:
- 27 Jostein Starrfelt
- 28 Department of Infection Control and Preparedness
- 29 Norwegian Institute of Public Health
- 30 Postboks 222 Skøyen
- 31 0213 Oslo, Norway
- 32 jostein.starrfelt@fhi.no
- 33 +47 21 07 70 00
- 34
- 35 Word count: 3858

36 Abstract

37	Background: COVID-19 vaccines have been crucial in the pandemic response and understanding changes
38	in vaccines effectiveness is essential to guide vaccine policies. Though the Delta variant is no longer
39	dominant, understanding vaccines effectiveness properties will provide essential knowledge to
40	comprehend the development of the pandemic and estimate potential changes over time.
41	
42	Methods: In this population-based cohort study, we estimated vaccine effectiveness against SARS-CoV-2
43	infections, hospitalisations, intensive care admissions, and death using Cox proportional hazard models,
44	across different vaccine product regimens and age groups, between 15 July and 31 November 2021
45	(Delta variant period). Vaccine status is included as a time-varying covariate and all models were
46	adjusted for age, sex, comorbidities, county of residence, country of birth, and living conditions. Data
47	from the entire adult Norwegian population were collated from the National Preparedness Register for
48	COVID-19 (Beredt C19).
49	Results: The overall adjusted vaccine effectiveness against infection decreased from 81.3% (confidence
50	interval (CI): 80.7 to 81.9) in the first two to nine weeks after receiving a second dose to 8.6% (CI:4.0 to
51	13.1) after more than 33 weeks, compared to 98.6% (CI: 97.5 to 99.2) and 66.6% (CI: 57.9 to 73.6) against
52	hospitalisation respectively. After the third dose (booster), the effectiveness was 75.9% (CI: 73.4 to 78.1)
53	against infection and 95.0% (CI: 92.6 to 96.6) against hospitalisation. Spikevax or a combination of mRNA
54	products provided the highest protection, but the vaccine effectiveness decreased with time since
55	vaccination for all vaccine regimens.

56 <u>Conclusions:</u> Even though the vaccine effectiveness against infection wanes over time, all vaccine
 57 regimens remained effective against hospitalisation after the second vaccine dose. For all vaccine

regimens, a booster facilitated recovery of effectiveness. The results from this support the use of

59 heterologous schedules, increasing flexibility in vaccination policy.

60 <u>Funding</u>: no external funding

61 <u>Key words</u>: COVID-19; SARS-CoV-2; COVID-19 Vaccines; Vaccine effectiveness; Proportional Hazards

62 Models; Intensive Care Units; Mortality; Hospitalization; Cohort Studies; Vaccination; Norway; Registries

63

64 Background

65 Since the start of the COVID-19 pandemic, various COVID-19 vaccines have been approved for

66 Emergency Use Listing/Authorization (EUL/EUA), including Comirnaty (Pfizer/BioNTech; BNT162b2),

67 Spikevax (Moderna; mRNA-1273), Vaxzevria (AstraZeneca; ChAdOx nCoV-19; AZD1222), and Janssen

68 (Johnson & Johnson; Ad26.COV2.S). Both vaccine efficacy estimates from randomised controlled trials

69 and vaccine effectiveness estimates from observational studies in the first months after the vaccine roll-

70 out showed strong protection against both infection and severe disease.¹⁻⁶ However, effectiveness may

71 differ between product types and against different virus variants, as well as be affected by dose intervals

72 or population structure (age distribution, risk groups).⁷⁻¹³ Many countries have adopted flexible policies

allowing "mixing and matching" of vaccines (heterologous regimens) during SARS-CoV-2 vaccination

campaigns, in response to supply constraints, policy changes or rare but severe side effects associated

75 with the vector-based vaccines.^{14,15} Combining the vector-based vaccines, such as Vaxzevria, with an

76 mRNA vaccine increases the vaccine effectiveness to a level comparable with mRNA regimens.^{7,16-18}

77 Nonetheless, a possible waning of vaccine-induced immunity could result in lower vaccine effectiveness

78 over time.^{19,20} Recently published data suggest reduced protection against SARS-CoV-2 infection in all

age groups six months after the completion of a primary vaccination regimen, and also, a small decrease
 against severe disease in certain groups.²¹

81	On 27 December 2020, Norway started COVID-19 vaccination, initially targeted towards elderly (>65
82	years) and risk groups. Of those ≥18 years, 88% had received at least two vaccine doses by 5 December
83	2021. Vaxzevria was included in the Norwegian national vaccine programme until 11 March 2021; those
84	who received one dose were offered a second dose with an mRNA vaccine. Since September 2021, a
85	booster dose has been recommended, initially prioritising those above 65 years and risk groups,
86	including health care workers. From early February 2021, the Alpha variant (B1.1.7) was the dominant
87	circulating strain in Norway, being replaced by the Delta variant (B.1.617.2) by July and Omicron by
88	December 2021. ^{5,7,8}
89	Understanding the changes in vaccines effectiveness over time, the impact of giving boosters, and
90	differences between vaccine types, is essential to guide vaccine implementation and policies. Even
91	though the Delta variant is no longer dominant in many regions, understanding these properties will
92	provide essential knowledge that can be used to understand the development of the pandemic and
93	estimate potential changes over time. The purpose of this study is to quantify and compare the vaccine

94 effectiveness against infection, disease, and death achieved in the Norwegian population during the

95 Delta epidemic considering time since vaccination, vaccine type and age groups.

96 Methods

97 <u>Study population</u>

For this population-based cohort study, we collated data from the Norwegian National Preparedness
Register for COVID-19 (Beredt C19) (Supplementary table S1), which contains individual-level data from
national central health registries, national clinical registries, and other national administrative registries.
We included all adults (≥18 years by the end of 2021) with a valid national identity number and
registered in the National Population Registry (NPR) as living in Norway. To remove non-standard
vaccination histories, we removed individuals with more than three doses before the end of the study
period (1 348 individual) and excluded individuals for which the interval between first and second dose

105	was shorter than the recommended minimum intervals (678 individuals), and censored those with a
106	third dose registered before the recommended 120 days of the second dose (17 497 individuals). The
107	recommended minimum interval between first and second dose was based on the vaccine type given as
108	the first dose; 19 days for Comirnaty, 22 days for Spikevax, and 21 days for Vaxzevria. We only included
109	individuals who had received either of the three vaccines that are part of the Norwegian vaccination
110	programme (Comirnaty, Spikevax or Vaxzevria), excluding a further 6 257 individuals. Finally, 67
111	individuals admitted to hospital with COVID-19 without a corresponding match in the database for the
112	time of positive test were excluded. Data were extracted from the registries on 15 February 2022.
113	Definitions
114	SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian
115	Surveillance System for Communicable Diseases (MSIS) registry. Individuals who were hospitalised or
116	admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry
117	(NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for
118	admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an
119	ICU (length of stay ≥24 hours), required mechanical ventilatory support (invasive or non-invasive), or
120	persistent administration of vasoactive medication. All COVID-19 associated deaths are defined as
121	anyone with a positive SARS-CoV-2 PCR test who died with COVID-19 reported on the death certificate in
122	the Cause of Death Register (DÅR), or those notified directly to MSIS. We use testing date as time of
123	infection (positive PCR test) and vaccination status is determined at time of infection for all outcomes.
124	Individual vaccination histories were generated from the Norwegian Immunisation Registry (SYSVAK),
125	and categorised into the following vaccination statuses:
126	- Unvaccinated: unvaccinated up to seven days before the first dose
127	- 1^{st} dose: ≥ 21 days after first vaccine dose up to seven days after second vaccine dose
128	- 2^{nd} dose: >7 days after the 2^{nd} dose, divided in period of eight weeks

129

130

- 3rd dose (booster): >7 days after a vaccine dose given 120 days or more after completion of the primary vaccine regimen

131 The vaccine regimens included were Comirnaty, Spikevax, heterologous mRNA regimen, Vaxzevria, or 132 Vaxzevria in combination with an mRNA vaccine, all with or without an mRNA booster. The period 133 between seven days before the first vaccine dose until 21 days after the first dose was included as a 134 separate status not reported, since vaccination was postponed if individuals showed signs of infection 135 which could potentially bias infection rates for both unvaccinated and partially vaccinated if included in 136 the adjacent vaccination statuses. Similarly, individuals were also included as a separate status and not 137 reported for the first seven days after receiving the third dose. Individuals with a SARS-CoV-2 infection 138 registered prior to 1 June 2021 were included as a separate category (see below). 139 To adjust for confounding, several covariates were included in our analysis. When stratifying by age, we 140 used the categories 18 to 44 years, 45 to 64 years, and 65 years or older. For adjustment in other 141 models, we used 10-year age bands (NPR). County of residence (NPR) was included as both infection 142 rates and speed of vaccine rollout has varied across Norway. We included country of birth (NPR; Norway, 143 abroad or unknown) and crowded living conditions (Statistics Norway; crowded, not crowded, or 144 unknown) since both are associated with vaccine coverage and risk of infection. Individuals with pre-145 existing medical conditions associated increased risk of severe COVID-19 illness were prioritised for 146 vaccination and this covariate was also included in the adjusted model. Missing values were considered 147 as a separate category for each of the variables where relevant. More details on the data sources, and 148 variables can be found in the supplementary information as well as the number of infections, 149 hospitalisations, and vaccination status over time (figures S1 and S2).

150 Data analyses

We estimated the vaccine effectiveness using Cox proportional hazards models on an open cohort, using vaccine status as time-varying covariate for all individuals included in the statistical software R^{18} . We

included all SARS-CoV-2 infections reported from 15 July until 30 November 2021, the period in which
the delta variant was dominating in Norway.¹⁰ We right-censored individuals at the time of an event
(SARS-CoV-2 infection, hospitalisation, ICU admission or death associated with COVID-19), time of death
(all cause) or end of follow-up period (30 November). During the study period, the registries in Norway
only report re-infections if six months or more since last positive test, individuals registered with an
infection prior to 15 July 2021 entered the dataset 180 days since positive test with status 'previously
infected'.

Vaccine effectiveness is defined as $100^{*}(1-\beta)$, where β represents the hazard ratio associated with a particular vaccine status. For crude vaccine effectiveness estimates, we only used vaccine status as a time-varying covariate (supplementary analyses). For adjusted estimates, we implemented stratified analyses using *strata(variable)* in the *survival*-package¹⁷, i.e. that the impact of the adjustment variables can be non-proportional.

165 To estimate specific vaccine effectiveness for age groups and vaccine product regimens, we use 166 independent Cox-models while still adjusting for the remaining covariates as strata. Vaccine status was 167 factored either by combining all vaccine types (thus assuming similar effectiveness across vaccines) to 168 estimate a population level vaccine effectiveness of the vaccination program in Norway or by 169 implementing vaccine status as the combination of vaccine type and vaccine status. Due to the smaller 170 numbers and partial exclusion of Vaxzevria from the vaccination program in Norway, all individuals who 171 received a dose of Vaxzevria were censored at time of the dose in the product specific analyses. Models 172 were also run excluding all unvaccinated individuals who have never had a recorded SARS-CoV-2 PCR test 173 in Norway, results from these models can be found in the supplementary materials (subcohort 1).

- 175 In total, 75 303 were diagnosed with SARS-CoV-2 infection, 1 438 were hospitalised with COVID-19 as main cause for admission, 289 were
- admitted to the ICU, and 331 died with COVID-19 between 15 July and 30 November 2021. Characteristics of the study population and by
- 177 outcome can be found in Table 1. Overall vaccine effectiveness against infection was estimated at 24.7 % (confidence interval/CI: 22.7 to 26.7)
- after the first dose, 65 .2 % (CI: 64 .6 to 65 .9) after the second dose and 84.8 % (CI: 83.3 to 86.3) after the third dose. Previous infections reduced
- the probability of infection by 93.5 % (CI: 92.7 to 94.2).
- 180

181 Table 1: Study population

		Total study population		SARS-CoV-2 infection		Hospitalisation		ICU admission		COVID-19 deaths	
		n	%	n	%	n	%	n	%	n	%
All	-	4 301 995	-	74 371	-	1 429	-	290	-	331	-
Age groups	18-24 years	457 238	10.6	11 4 99	15.5	24	1.7	1	0.3	0	0.0
	25-34 years	747 249	17.4	16 013	21.5	113	7.9	16	5.5	2	0.6
	35-44 years	705 460	16.4	17 131	23.0	190	13.3	40	13.8	2	0.6
	45-54 years	735 420	17.1	14 050	18.9	206	14.4	46	15.9	6	1.8
	55-64 years	653 259	15.2	7 440	10.0	202	14.1	63	21.7	22	6.6
	65-74 years	540 898	12.6	4 604	6.2	214	15.0	52	17.9	38	11.5
	75-84 years	335 628	7.8	2 557	3.4	301	21.1	59	20.3	103	31.1
	≥85 years	126 843	2.9	1 077	1.4	179	12.5	13	4.5	158	47.7

Sex	Male	2 160 307	50.2	37 098	49.9	791	55.4	196	67.6	185	55.9
	Female	2 141 688	49.8	37 2 7 3	50.1	638	44.6	94	32.4	146	44.1
Underlying conditions	No risk group	3 401 381	79.1	62 802	84.4	711	49.8	129	44.5	78	23.6
	Medium risk	788 954	18.3	10 247	13.8	524	36.7	115	39.7	180	54.4
	High Risk	111 660	2.6	1 322	1.8	194	13.6	46	15.9	73	22.1
Country of birth	Norway	3 202 876	74.5	46 501	62.5	791	55.4	170	58.6	247	74.6
	Outside Norway	802 615	18.7	25 579	34.4	506	35.4	103	35.5	34	10.3
	Unknown	296 504	6.9	2 291	3.1	132	9.2	17	5.9	50	15.1
Crowding	Yes	336 777	7.8	11 953	16.1	175	12.2	29	10.0	7	2.1
	No	3 728 263	86.7	57 206	76.9	1 154	80.8	238	82.1	299	90.3
	Unknown	236 955	5.5	5 212	7.0	100	7.0	23	7.9	25	7.6

182 Table 1 Characteristics of study population and by outcomes of interests; SARS-CoV-2 infections, hospitalisation, ICU admission and death, Norway, 15 July – 30

183 November 2021

184

186 Vaccine effectiveness since time of vaccination

187 The adjusted vaccine effectiveness against infection was high in the first period (two to nine weeks) after 188 the second dose (81.3 %, CI: 80.7 to 81.9). Effectiveness waned with time since vaccination and more 189 than 33 weeks after receiving the second dose the effectiveness against infection was 8.6 % (CI: 4.0 to 190 13.4). Similarly, the effectiveness against hospitalisation was 98.6 % (CI: 97.5 to 99.2) in the period right 191 after receiving the second dose, decreasing to 66.6 % (CI: 57.9 to 73.6) after more than 33 weeks. For 192 admission to intensive care unit and death, not enough events in the first period following the second 193 dose had occurred to reliably estimate a vaccine effectiveness, but in the following period (10 to 17 194 weeks), vaccine effectiveness was 96.9 % (CI: 94.7 to 98.1) and 93.4 % (CI: 85.4 to 97.0) against ICU and 195 death respectively, with a less pronounced reduction over time for ICU admissions (86.7%, CI: 73.9 to 196 93.2 after more than 33 weeks) than for death (68.6%, CI: 55.4 to 77.9). One dose provided little 197 protection against infection (30.0 %, CI: 28.2 to 31.9), but did protect against hospitalisation (79.4 %, CI: 198 73.0 to 84.2), ICU admission (92.4 %, CI: 80.9 to 97.0) though not death (46.9 %, CI: -0.2 to 71.9). The 199 vaccine effectiveness against infection after receiving a third dose (75.9 %, CI: 73.4 to 78.1) was similar to 200 the effectiveness in the initial two to nine weeks after the second dose (81.3 %, CI: 80.7 to 81.9). For 201 those with a previous reported infection (>6 months prior), the protection against infection was 93.1 % 202 (CI: 92.3 to 93.9), whereas too few events among those with a reported prior infection were reported to 203 estimate effectiveness against hospitalisation. Vaccine effectiveness for all outcomes split by time are 204 shown in Figure 1 (details S2-S5). 205 Vaccine effectiveness by age

206 Vaccine effectiveness against infection was highest in two to nine weeks after the second dose among

207 18- to 44-year-olds (83.2 %; CI: 82.6 to 83.8) compared to 45- to 64-year-olds (75.6 %; CI: 74.1 to 77.0)

and those over 64 years (74.9 %; CI: 67.2 to 80.7). No significant protection was found more than 33

209 weeks after the second dose: the estimated effectiveness against infection was 5.2 % (CI: -1.9 to 11.8) for

210	18- to 44-year-olds, 0.5 % (Cl: -9.4 to 9.5) among 45- to 64-year-olds and 8.4 % (-2.8 to 18.5) among
211	those over 65 years (Figure 2, Table S6). Among those with a reported prior infection, protection against
212	infection was 92.6 % (CI: 91.5 to 93.5), 95.1 % (CI: 93.6 to 96.3) and 89.0 % (CI: 81.3 to 93.5) for 18- to 45-
213	year-olds, 45- to 64-year-olds and over 65-yea-olds respectively (Figure 2). The protection against
214	hospitalisation was already significant after one dose in all age groups: 82.9 % (CI: 73.0 to 89.2) among
215	18- to 44-year-olds, 71.4 % (56.2 to 81.4) among 45- to 64-year-olds and 56.5 % (CI: 24.6 to 74.9) among
216	those over 65 years. The effectiveness against hospitalisation decreased less with time than protection
217	against infection. For 45- to 64-year-olds the effectiveness was 99.1 % (CI: 97.7 to 99.6) in two to nine
218	weeks after the second dose, compared to 65.3 % (CI: 33.3 to 82.0) more than 33 weeks after the second
219	dose. Similarly, among those above 65 years, the protection waned from 93.6 % (CI: 89.9 to 96.0) to 61.9
220	% (CI: 50.1 to 70.9) (Figure 2, supplementary tables S6 and S7). Receiving a third dose increased vaccine
221	effectiveness against hospitalisation to 85.4 % (CI: 65.3 to 93.9) amongst 45- to 64-year-olds and 95.3 %
222	(CI: 92.6 to 97.0) for over 65-year-olds; the number of events were too small for 18- to 44-year-olds
223	(Figure 2, supplementary tables S6 and S7).

224

225 Vaccine effectiveness by product regimen

When stratifying by product regimen, individuals who received two doses of Spikevax (86.6%; CI: 85.6 to
87.6) or a heterologous mRNA regimen (84.1%; CI: 83.2 to 85.0) had a higher estimated vaccine
effectiveness against infection than those who received two doses Comirnaty (77.7%; CI: 76.8 to 78.5) in
two to nine weeks after the second dose (Figure 3, table S8). All product regimens showed waning of
vaccine effectiveness against infection. The vaccine effectiveness against infection after receiving the
third dose was highest for those who received two doses of Spikevax followed by a booster with
Comirnaty (87.1%; CI: 80.1 to 91.6) or Spikevax (84.9%; CI: 71.8 to 91.9), compared to 75.3% (CI: 72.5 to

233	77.8) and 68.2 % (CI: 57.6 to 76.1) for those who received two doses of Comirnaty followed by a booster
234	with Comirnaty or Spikevax respectively. The vaccine effectiveness against hospitalisation was high after
235	one dose (77.1% and 75.3%) for both Spikevax and Comirnaty, as well as one to 32 weeks after the
236	second dose (range 81.8 to 97.5%). There were only five hospital admissions among those who received
237	heterologous mRNA vaccination during our study period and therefore vaccine effectiveness against
238	hospitalisation since time of vaccination could not be estimated. Among those who received a booster
239	dose, vaccine effectiveness against hospitalisation could only be estimated for those with primary
240	regimen of Comirnaty and protection was high 95.6 % (CI: 93.1 to 97.2) for those receiving a Comirnaty
241	booster, but slightly lower but more uncertain for those receiving Spikevax (73.5%; CI: 45.7 to 87.1)
242	(Figure 3, table S9).
243	Discussion
244	Our analyses showed strong protection against SARS-CoV-2 infection in the first period after two or more
245	vaccine doses for both homologous and heterologous mRNA regimens. However, for all product
246	regimens and age groups, the vaccine effectiveness against infection waned over time. Vaccine
247	effectiveness against hospitalisation was high for all product regimens and age groups, with limited
248	waning with time since vaccination.
249	
250	Our findings are consistent with other studies investigating waning of vaccine effectiveness, as
251	summarised through a systematic review by Feikin et al. ²¹ Most observational studies employ a test-
252	negative study design, while some are register-based cohort studies like ours. ^{19,25-33} We reported large
253	waning of effectiveness against SARS-CoV-2 infection, which could have several explanations. First, we
254	have a longer follow-up time than previously published studies. Second, we use data from a high-quality
255	population register covering an entire national population in a country with widespread and free testing
256	irrespective of symptoms. After vaccination, individuals might modify their behaviour based on

257 evaluating risk and change propensity for testing, or unvaccinated could become indirectly protected by 258 an increasing population immunity. In addition, unrecorded prior infections among unvaccinated may 259 reduce the detected risk among unvaccinated. The estimates from this study are possibly conservative; 260 excluding those reported as unvaccinated who have never been tested resulted in higher vaccine 261 effectiveness for all outcomes (supplemental tables S2-S5, subcohort 1). Our findings are in line with immunological findings suggesting that antibody titres wane over time.^{20,34} Even though antibody-262 263 mediated immunity may wane and require time to reactivate upon infection, the fact that vaccine 264 effectiveness against severe disease remains high is consistent with the induction of cell-mediated 265 immunity.³⁵ While groups at risk for more severe outcome form a disproportionate part of those 266 hospitalized, admitted to ICU or death (Table 1), an analysis of a subcohort excluding all risk groups 267 showed similar estimates of vaccine effectiveness (supplemental tables S2-S5, subcohort 2), which 268 indicates that the vaccines reduce the probabilities of infection and hospitalisation similarly across risk-269 groups.

To our knowledge, this is among the few studies to report on the vaccine effectiveness of heterologous mRNA vaccine regimens. As heterologous vaccine regimens were accepted in Norway from June 2021, recipients of a combination of mRNA vaccines are predominantly younger and healthier. However, these results are also maintained across age groups and are in line with a test-negative case control study from Canada.²⁸ In addition, we show that Spikevax shows a slightly higher vaccine effectiveness against infection than Comirnaty, as has also been reported by others.^{9,37,38}

276 During our study period, many aspects of the disease dynamics changed, and changes also occurred 277 simultaneously. This leads to difficulties in correctly identifying the mechanisms and factors driving the 278 system. Even though we attempt to control for these factors in the analyses, residual confounding 279 cannot be excluded. Furthermore, testing intensity changed over time, especially with the introduction 280 of self-administered rapid antigen tests after last summer. Even though testing capacity is high in

281 Norway, all individuals infected with SARS-CoV-2 have not been detected, which could affect the 282 estimates since the proportion of unidentified cases may differ dependent on age as well as on vaccine 283 status.²⁹ Additionally, the estimated vaccine effectiveness can be affected by number and types of contacts.³⁰ As previously mentioned, the vaccine effectiveness could be underestimated if getting 284 285 vaccinated results in behavioural changes associated with higher risk of exposure. We are not able to 286 model these effects in our analyses. Nevertheless, the estimated population-level effects can provide a 287 reasonable estimate of the individual-level vaccine efficacy since the total attack rate during the study period was small.³⁰ 288

289 The ability to link data collected via national registries is a great advantage and allows us to estimate 290 population-wide vaccine effectiveness. However, some limitations of register-based data should be 291 considered when interpreting the results. Data in these registries are not collected for the purpose of 292 this study, and therefore the focus on level of detail, error checking and precision in the available data is 293 not guided by the current study, as would be the case for independent data gathering. For instance, 294 while vaccines administered as part of the Norwegian vaccination program should be in our dataset, it is 295 not unlikely that some have received vaccines outside Norway and not reported them to the Norwegian 296 register (SYSVAK). While limitations in register-based data are important caveats – our cohort study 297 encompassing the whole Norwegian adult population indicates that vaccine effectiveness against severe 298 disease is high among vaccinated individuals. Our estimates remain gualitatively the same for protection 299 against infection and severe disease when splitting by age groups, indicating that the confounding effect 300 of factors that are relatively constant within age-groups introduce little bias in our adjusted models. 301 Appropriate prioritisation and planning of vaccine campaigns is integral for combating COVID-19 and is 302 only possible with updated knowledge on vaccine effectiveness of realistic vaccination regimens 303 achieved in large populations. For our study the overall protection (i.e. a weighted mean of vaccine

304 effectiveness over time) increase through the initial period with a peak of right below 60% on the 21st of

305	September (Supplemental figure S3). Coupling VE-estimates with cohort fractions over time can yield
306	valuable information on the general level of protection in a population and timing and prioritisation of
307	vaccine roll-out. Our study among adults in Norway indicate a high vaccine effectiveness against both
308	infection and hospitalisation with both homologous and heterologous mRNA regimens. Even though the
309	effectiveness against infection declines with time since vaccination, the protection against severe disease
310	remained high. The results support the use of heterologous regimens, increasing flexibility in vaccination
311	policy.
312	Conclusions
313	During the Delta-phase of the COVID-19 epidemic in Norway, vaccine effectiveness against infection
314	clearly waned over time, however, all vaccine regimens remained effective against hospitalisation after
315	the second vaccine dose. For all vaccine regimens, a booster facilitated recovery of effectiveness. The
316	results from this support the use of heterologous schedules, increasing flexibility in vaccination policy.
317	
318	
319	Declarations
320	Ethics approval
321	Ethical approval was granted by Regional Committees for Medical and Health Research Ethics (REC)
322	Southeast (reference number 122745). The Norwegian Institute of Public Health has performed a Data
323	Protection Impact Assessment (DPIA) for Beredt C19.
324	Competing interests

325 All authors declare no competing interest.

326 **Consent for publication**

- 327 Not applicable.
- 328 Funding
- 329 All data collection and work related to the study design, analyses and manuscript preparation was
- 330 performed without external funding.

331 Availability of data and materials

- 332 The datasets analysed during the current study come from the national emergency preparedness registry
- for COVID-19 (Beredt C19), housed at the Norwegian Institute of Public Health. The preparedness
- registry comprises data from a variety of central health registries, national clinical registries, and other
- national administrative registries. Legal restrictions prevent the researchers from sharing the dataset
- used in the study. However, external researchers are freely able to request access to linked data from
- the same registries from outside the structure of Beredt C19, as per normal procedure for conducting
- health research on registry data in Norway (https://www.helsedata.no). Further information on the
- 339 preparedness registry, including access to data from each data source, is available at
- 340 https://www.fhi.no/en/id/infectiousdiseases/coronavirus/emergency-preparedness-register-for-covid-
- 341 <u>19/</u>Code and model results in summary form from R is available from the author.

342 Authors' contribution

- JS and HM developed the concept and design for the study. JS performed data analyses, TL, AD, and GR
- verified the underlying data and model code. JS, AD and HM interpreted the data and drafted the
- 345 manuscript with inputs from SW, GR, TL, EB, LV and LJ. All authors had the opportunity to request data
- access. All authors contributed to and approved the submitted version.

347 Acknowledgements

- 348 The authors greatly appreciate the efforts of all health professionals in vaccinating over 4 million
- 349 Norwegians and performing over eight million PCR tests, and in addition managing to report these
- events to form the data for this analysis. We also acknowledge the efforts of employees at hospitals
- around Norway in the reporting of timely and complete data to the Norwegian Intensive Care and
- 352 Pandemic Registry, as well as staff in the registry administration. Additional appreciation is given to all
- 353 contributors to the development and inner workings of Beredt C19.

354

356 References

- 1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
- 358 Vaccine. *N Engl J Med* 2021; **384**(5): 403-16.
- 2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
- 360 Vaccine. *N Engl J Med* 2020; **383**(27): 2603-15.
- 361 3. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
- 362 Vaccine through 6 Months. *N Engl J Med* 2021.
- 363 4. Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases,
- Hospitalizations, and Deaths, by Vaccination Status 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR
- 365 *Morb Mortal Wkly Rep* 2021; **70**(37): 1284-90.
- 366 5. Higdon MM, Wahl B, Jones CB, et al. A systematic review of COVID-19 vaccine efficacy and
- 367 effectiveness against SARS-CoV-2 infection and disease. *medRxiv* 2021: 2021.09.17.21263549.
- 368 6. Fan YJ, Chan KH, Hung IF. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and
- 369 Meta-Analysis of Different Vaccines at Phase 3. *Vaccines (Basel)* 2021; **9**(9).
- 370 7. Gram MA, Nielsen J, Schelde AB, et al. Vaccine effectiveness when combining the ChAdOx1
- vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose. *medRxiv* 2021:
- 372 2021.07.26.21261130.
- 8. Moghadas SM, Vilches TN, Zhang K, et al. Evaluation of COVID-19 vaccination strategies with a
- delayed second dose. *PLoS Biol* 2021; **19**(4): e3001211.
- 9. Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for
- 376 COVID-19 during periods of Alpha and Delta variant prevalence. *medRxiv* 2021.
- 10. Seppala E, Veneti L, Starrfelt J, et al. Vaccine effectiveness against infection with the Delta
- 378 (B.1.617.2) variant, Norway, April to August 2021. Euro Surveill 2021; 26(35).

- 11. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health S, the EIIC. SARS-CoV-2 Delta VOC
- in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* 2021;
- **381 397**(10293): 2461-2.
- 12. Veneti L, Seppälä E, Larsdatter Storm M, et al. Increased risk of hospitalisation and intensive care
- admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway,
- 384 December 2020 May 2021. *PLoS One* 2021; **16**(10): e0258513.
- 13. Veneti L, Valcarcel Salamanca B, Seppälä E, et al. No difference in risk of hospitalisation between
- reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway. *medRxiv* 2021:
- 387 2021.09.02.21263014.
- 14. Lewis D. Mix-and-match COVID vaccines: the case is growing, but questions remain. *Nature*
- 389 2021; **595**(7867): 344-5.
- 15. Lu S. Heterologous prime-boost vaccination. *Curr Opin Immunol* 2009; **21**(3): 346-51.
- 16. Tenbusch M, Schumacher S, Vogel E, et al. Heterologous prime-boost vaccination with ChAdOx1
- 392 nCoV-19 and BNT162b2. *Lancet Infect Dis* 2021; **21**(9): 1212-3.
- 17. Normark J, Vikstrom L, Gwon YD, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273
- 394 Vaccination. *N Engl J Med* 2021; **385**(11): 1049-51.
- 18. Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA
- 396 prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study.
- 397 The Lancet Regional Health Europe 2021: 100249.
- 398 19. Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity of the BNT162b2 vaccine: A
- nationwide study from Israel. *medRxiv* 2021: 2021.08.24.21262423.
- 400 20. Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19
- 401 Vaccine over 6 Months. *N Engl J Med* 2021.

- 402 21. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-
- 403 CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet* 2022.
- 404 22. Norwegian Institute of Public Health. Coronavirus vaccination statistics. 12.10.2021 2021.
- 405 https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/coronavirus-vaccination----
- 406 <u>statistic/</u> (accessed 10.11 2021).
- 407 23. Therneau TM. A Package for Survival Analysis in R, 2021.
- 408 24. R Core Team. A language and environment for statistical computing. , 2021.
- 409 25. Chua H, Feng S, Lewnard JA, et al. The Use of Test-negative Controls to Monitor Vaccine
- 410 Effectiveness: A Systematic Review of Methodology. *Epidemiology* 2020; **31**(1): 43-64.
- 411 26. Poukka E, Baum U, Palmu AA, et al. Cohort study of Covid-19 vaccine effectiveness among
- 412 healthcare workers in Finland, December 2020 October 2021. *medRxiv* 2021: 2021.11.03.21265791.
- 413 27. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6
- 414 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet* 2021.
- 415 28. Martinez-Baz I, Trobajo-Sanmartin C, Miqueleiz A, et al. Product-specific COVID-19 vaccine
- 416 effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro
- 417 Surveill 2021; **26**(39).
- 418 29. Lin D-Y, Gu Y, Wheeler B, et al. Effectiveness of Covid-19 Vaccines in the United States Over 9
- 419 Months: Surveillance Data from the State of North Carolina. *medRxiv* 2021: 2021.10.25.21265304.
- 420 30. Nordström P, Ballin M, Nordström A. Effectiveness of Covid-19 Vaccination Against Risk of
- 421 Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort
- 422 Study. *Preprint* 2021.
- 423 31. Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe Disease by
 424 Covid-19 Vaccines. *N Engl J Med* 2022; **386**(4): 340-50.

- 425 32. Fabiani M, Puopolo M, Morciano C, et al. Effectiveness of mRNA vaccines and waning of
- 426 protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta
- 427 variant in Italy: retrospective cohort study. *BMJ* 2022; **376**: e069052.
- 428 33. Nordstrom P, Ballin M, Nordstrom A. Risk of infection, hospitalisation, and death up to 9 months
- 429 after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.
- 430 *Lancet* 2022; **399**(10327): 814-23.
- 431 34. Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six
- 432 months: a longitudinal prospective study. *Lancet Reg Health Eur* 2021; **10**: 100208.
- 433 35. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19
- 434 and SARS, and uninfected controls. *Nature* 2020; **584**(7821): 457-62.
- 435 36. Skowronski DM, Setayeshgar S, Febriani Y, et al. Two-dose SARS-CoV-2 vaccine effectiveness
- 436 with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia
- 437 and Quebec, Canada. *medRxiv* 2021: 2021.10.26.21265397.
- 438 37. Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of
- 439 Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. *medRxiv* 2021:
- 440 2021.09.15.21263583.
- 441 38. European Centre for Disease Prevention and Control. Interim public health considerations for the
 442 provision of additional COVID-19 vaccine doses, 2021.
- 443 39. Tunheim G, Kran A-MB, Rø G, et al. Seroprevalence of SARS-CoV-2 in the Norwegian population
- 444 measured in residual sera collected in January 2021 Oslo: The Norwegian Institute of Public Health, 2021.
- 445 40. Haber M, Halloran ME, Longini Jr. IM, Watelet L. Estimation of Vaccine Efficacy in Non-Randomly
- 446 Mixing Populations. *Biometrical Journal* 1995; **37**(1): 25-38.
- 447

448

449 Figures



450

Figure 1 Adjusted vaccine effectiveness against infection (red), hospitalisation (blue), ICU admission
(yellow) and COVID-19 associated deaths (orange) for Norwegian adults using data from 15 July - 30
November 2021. Adjusted for age, sex, comorbidities, county of residence, country of birth, and living
conditions.







456

Figure 2 Adjusted vaccine effectiveness against infection (A) and hospitalisation (B) for age 18-44 years
(blue), 45 to 64 (pink) and 65+ years (green) among Norwegian adults using data from 15 July – 30
November 2021. Adjusted for age, sex, comorbidities, county of residence, country of birth, and living
conditions.



Vaccine effectiveness - hospitalisation



462

Figure 3 Adjusted vaccine effectiveness against infection (A) and hospitalisation (B) per vaccine product
regimen (Spikevax (blue), Comirnaty (pink) or mixed mRNA primary regimen (dark green) and mixed
booster (light green and yellow) among Norwegian adults using data from 15 July – 30 November 2021.
Adjusted for age, sex, comorbidities, county of residence, country of birth and living conditions. mRNA
includes a combination of one dose Spikevax and one dose Comirnaty; only few individuals who received
a heterologous primary regimen were eligible for a booster during the study period and are therefore not
included

470